Lavior Pharma Welcomes Dr. Imaze Marian Davis as New Chief Medical Officer

Lavior Pharma's Exciting New Chapter

Lavior Pharma Inc., a distinguished woman-owned pharmaceutical company known for its commitment to developing innovative therapies for both chronic and acute conditions, is thrilled to announce the appointment of Dr. Imaze Marian Davis as its new Chief Medical Officer. This strategic addition underscores Lavior's dedication to clinical excellence and leadership by women in the industry.

A Distinguished Background

Dr. Imaze Marian Davis, DPM, MBA, DABPM, CWSP, DABMSP, FACPM, FFPM RCPS (Glasg), brings nearly two decades of extensive experience in wound care and diabetic foot initiatives. Her pivotal role on Lavior's Advisory Board over the past two years showcases her impressive contributions to clinical-trial design and protocol development. Her educational background includes a Doctorate in Podiatric Medicine and an MBA from Barry University, completed in 2006.

After finishing her surgical residency at Westchester General Hospital, Dr. Davis served as the Director of the Wound Healing Center at North Shore Medical Center. Under her leadership, the center became a regional referral hub, noted for its significant reduction in amputation rates—an achievement that speaks volumes about her capabilities.

Recognizing Excellence and Diversity

The decision to appoint Dr. Davis was celebrated by both Anabelle Savion, Co-Founder and COO, and Gilad Savion, CEO. They emphasized that Dr. Davis’s unique blend of clinical expertise and strategic insight will be essential in advancing Lavior's pipeline. Her board certifications and established credentials in wound care, podiatric surgery, and diabetic management are viewed as vital assets in pushing the company’s innovative protocols forward.

Anabelle Savion expressed excitement about Dr. Davis’s appointment, stating, "Dr. Davis brings an extraordinary blend of clinical expertise, surgical acumen, and strategic vision. Appointing a distinguished woman physician as CMO reflects our values of diversity, equity, and excellence."

Similarly, CEO Gilad Savion highlighted Dr. Davis's dedication to reducing amputations through innovative protocols and her passion for mentorship within the medical field, aligning perfectly with Lavior’s mission. "I look forward to Dr. Davis's guidance as we accelerate clinical programs and bring new treatments to market," he stated.

Leading with Innovation

The appointment of Dr. Davis to this executive role comes as Lavior Pharma focuses on launching next-generation therapies aimed at treating diabetic foot ulcers and other challenging wounds. Dr. Davis’s commitment to improving patient outcomes and her initiative,